These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33580158)

  • 1. Inclusion of genetic variants in an ensemble of gradient boosting decision trees does not improve the prediction of citalopram treatment response.
    Shumake J; Mallard TT; McGeary JE; Beevers CG
    Sci Rep; 2021 Feb; 11(1):3780. PubMed ID: 33580158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.
    Athreya AP; Neavin D; Carrillo-Roa T; Skime M; Biernacka J; Frye MA; Rush AJ; Wang L; Binder EB; Iyer RK; Weinshilboum RM; Bobo WV
    Clin Pharmacol Ther; 2019 Oct; 106(4):855-865. PubMed ID: 31012492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
    JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genome-wide association study of a sustained pattern of antidepressant response.
    Hunter AM; Leuchter AF; Power RA; Muthén B; McGrath PJ; Lewis CM; Cook IA; Garriock HA; McGuffin P; Uher R; Hamilton SP
    J Psychiatr Res; 2013 Sep; 47(9):1157-65. PubMed ID: 23726668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining clinical variables to optimize prediction of antidepressant treatment outcomes.
    Iniesta R; Malki K; Maier W; Rietschel M; Mors O; Hauser J; Henigsberg N; Dernovsek MZ; Souery D; Stahl D; Dobson R; Aitchison KJ; Farmer A; Lewis CM; McGuffin P; Uher R
    J Psychiatr Res; 2016 Jul; 78():94-102. PubMed ID: 27089522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1.
    Nunez JJ; Nguyen TT; Zhou Y; Cao B; Ng RT; Chen J; Frey BN; Milev R; Müller DJ; Rotzinger S; Soares CN; Uher R; Kennedy SH; Lam RW
    PLoS One; 2021; 16(6):e0253023. PubMed ID: 34181661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.
    Adkins DE; Clark SL; Åberg K; Hettema JM; Bukszár J; McClay JL; Souza RP; van den Oord EJ
    Transl Psychiatry; 2012 Jul; 2(7):e129. PubMed ID: 22760553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.
    Fabbri C; Tansey KE; Perlis RH; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Breen G; Curtis C; Sang-Hyuk L; Newhouse S; Patel H; Guipponi M; Perroud N; Bondolfi G; O'Donovan M; Lewis G; Biernacka JM; Weinshilboum RM; Farmer A; Aitchison KJ; Craig I; McGuffin P; Uher R; Lewis CM
    Pharmacogenomics J; 2018 May; 18(3):413-421. PubMed ID: 29160301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.
    Clark SL; Adkins DE; Aberg K; Hettema JM; McClay JL; Souza RP; van den Oord EJ
    Psychol Med; 2012 Jun; 42(6):1151-62. PubMed ID: 22041458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.
    O'Connell CP; Goldstein-Piekarski AN; Nemeroff CB; Schatzberg AF; Debattista C; Carrillo-Roa T; Binder EB; Dunlop BW; Craighead WE; Mayberg HS; Williams LM
    Am J Psychiatry; 2018 Mar; 175(3):251-261. PubMed ID: 29241359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-trial prediction of treatment outcome in depression: a machine learning approach.
    Chekroud AM; Zotti RJ; Shehzad Z; Gueorguieva R; Johnson MK; Trivedi MH; Cannon TD; Krystal JH; Corlett PR
    Lancet Psychiatry; 2016 Mar; 3(3):243-50. PubMed ID: 26803397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Machine Learning Prediction of Quality of Life Improvement During Antidepressant Treatment of Patients With Major Depressive Disorder: A STAR*D and CAN-BIND-1 Report.
    Phaterpekar T; Nunez JJ; Morton E; Liu YS; Cao B; Frey BN; Milev RV; Müller DJ; Rotzinger S; Soares CN; Taylor VH; Uher R; Kennedy SH; Lam RW
    J Clin Psychiatry; 2023 Nov; 85(1):. PubMed ID: 37967350
    [No Abstract]   [Full Text] [Related]  

  • 13. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant.
    Katz AJ; Dusetzina SB; Farley JF; Ellis AR; Gaynes BN; Castillo WC; Stürmer T; Hansen RA
    Pharmacotherapy; 2012 Mar; 32(3):234-43. PubMed ID: 22392456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication.
    Joyce JB; Grant CW; Liu D; MahmoudianDehkordi S; Kaddurah-Daouk R; Skime M; Biernacka J; Frye MA; Mayes T; Carmody T; Croarkin PE; Wang L; Weinshilboum R; Bobo WV; Trivedi MH; Athreya AP
    Transl Psychiatry; 2021 Oct; 11(1):513. PubMed ID: 34620827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data.
    Taliaz D; Spinrad A; Barzilay R; Barnett-Itzhaki Z; Averbuch D; Teltsh O; Schurr R; Darki-Morag S; Lerer B
    Transl Psychiatry; 2021 Jul; 11(1):381. PubMed ID: 34238923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLC6A4 variation and citalopram response.
    Mrazek DA; Rush AJ; Biernacka JM; O'Kane DJ; Cunningham JM; Wieben ED; Schaid DJ; Drews MS; Courson VL; Snyder KA; Black JL; Weinshilboum RM
    Am J Med Genet B Neuropsychiatr Genet; 2009 Apr; 150B(3):341-51. PubMed ID: 18618621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal multi-step predictive modeling of remission in major depressive disorder using early stage treatment data; STAR*D based machine learning approach.
    Salem H; Huynh T; Topolski N; Mwangi B; Trivedi MH; Soares JC; Rush AJ; Selvaraj S
    J Affect Disord; 2023 Mar; 324():286-293. PubMed ID: 36584711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.
    Schatzberg AF; DeBattista C; Lazzeroni LC; Etkin A; Murphy GM; Williams LM
    Am J Psychiatry; 2015 Aug; 172(8):751-9. PubMed ID: 25815420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A genomewide association study of citalopram response in major depressive disorder.
    Garriock HA; Kraft JB; Shyn SI; Peters EJ; Yokoyama JS; Jenkins GD; Reinalda MS; Slager SL; McGrath PJ; Hamilton SP
    Biol Psychiatry; 2010 Jan; 67(2):133-8. PubMed ID: 19846067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Race, genetic ancestry and response to antidepressant treatment for major depression.
    Murphy E; Hou L; Maher BS; Woldehawariat G; Kassem L; Akula N; Laje G; McMahon FJ
    Neuropsychopharmacology; 2013 Dec; 38(13):2598-606. PubMed ID: 23827886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.